MRK Merck & Company Inc. (new)

85.36
0  0%
Previous Close 85.36
Open
Price To Book 7.98
Market Cap 219,771,646,838
Shares 2,574,644,410
Volume 9,690
Short Ratio 1.89
Av. Daily Volume 10,576,937

NewsSee all news

  1. Here's Why I'm Sticking With Merck
  2. Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
  3. Merck's Keytruda Gets 2nd Label Expansion Approval in June
  4. The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut
  5. AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced February 19, 2019.
KEYTRUDA - EORTC1325/KEYNOTE-054
Melanoma
Approval announced June 13, 2018.
Keytruda
Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016.
KEYNOTE-040 KEYTRUDA
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-183
Multiple myeloma
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-185
Multiple myeloma
Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS.
Keytruda
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
FDA Approval announced August 30, 2018. PDUFA date for sNDA September 20, 2019.
PIFELTRO (doravirine)
HIV
Approved May 18, 2017.
KEYTRUDA
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Phase 3 interim analysis by DMC advised trial to be discontinued due to lack of benefit vs risk.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Approval announced November 9, 2017.
Letermovir
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016. Updated data presented at ASCO 2017. HR 0.70. OS 10.3 months.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met. Announced October 11, 2017 that it will not seek regulatory approval.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Approved May 10, 2017.
Keytruda
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 data due 2020.
MK-7264
Chronic cough
Approval announced March 14, 2017.
KEYTRUDA
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.
KEYTRUDA
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
Approval announced May 30, 2017.
ISENTRESS
HIV-1
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approval announced June 12, 2018.
KEYTRUDA
Cervical cancer
Phase 3 data at ASCO noted median PFS 7.4 months vs 3.8 months for placebo. HR 0.53.
Lynparza (POLO)
Pancreatic cancer
FDA Approval announced April 11, 2019.
Keytruda - KEYNOTE-042
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
FDA approval announced October 30, 2018.
KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407
Squamous non-small cell lung cancer (sNSCLC)
Phase 3 data due 2H 2019.
Lynparza
Castration-Resistant Prostate Cancer
Approval announced October 5, 2018.
GARDASIL 9
Human Papilloma virus vaccine
Phase 3 data due 2H 2019.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 3 data released April 25, 2019 noted that monotherapy arm met noninferiority primary endpoint. Combo arm did not meet OS/PFS endpoints.
Keytruda KN-062
Gastric cancer
Phase 3 data February 19, 2019 did not meet primary endpoints.
Keytruda KN-240
Hepatocellular Carcinoma
Phase 3 data May 20, 2019 did not meet primary endpoint.
Keytruda KN-119
Triple negative breast cancer (TNBC)
FDA Approval announced June 11, 2019.
Keytruda KN-048
Head and neck squamous cell carcinoma (HNSCC)
Phase 3 data due 2019
Keytruda KN-522
Triple negative breast cancer (TNBC)
FDA approval announced November 9, 2018.
Keytruda - KEYNOTE-224
Hepatocellular carcinoma (HCC)
FDA approval announced August 16, 2018.
LENVIMA (lenvatinib)
Hepatocellular Carcinoma (HCC)
FDA Approval announced December 19, 2018.
Keytruda KN-17
Merkel Cell Carcinoma
FDA approval announced June 3, 2019.
ZERBAXA(ceftolozane and tazobactam)
Hospital-acquired bacterial pneumonia (HABP)
Phase 1 data at ESMO October 2018 noted zero responses in monotherapy arm, 24% with Keytruda.
MK-1454 - STING
Solid tumors
FDA approval announced April 22, 2019.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
Phase 3 data due 2020.
Vericiguat
Heart Failure
Phase 3 data due 2019.
Keytruda KN-355
Triple negative breast cancer (TNBC)
Phase 3 trial did not meet primary endpoint of OS in intend-to-treat population. Endpoint met in squamous cell carcinoma or adenocarcinoma groups.
Keytruda KN-181
Esophageal Cancer
Phase 3 data due 2019.
Keytruda KN-177
Colorectal cancer (CRC)
Phase 3 data due 2019.
Keytruda KN-361
Bladder cancer
Phase 3 data due 2019.
Keytruda KN-057
NMIBC Bladder cancer
Phase 3 data due 2019.
Keytruda KN-604
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
LENVIMA (lenvatinib) + Keytruda - KN-581
Renal cell carcinoma (RCC) - cancer
Rolling BLA filing has commenced - noted November 13, 2018.
V920
Ebola
PDUFA date for sNDA September 20, 2019.
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate)
HIV
Phase 3 data due 2020.
Keytruda KN-122
Nasopharyngeal Carcinoma
PDUFA date under priority review July 16, 2019.
Imipenem/ cilastatin
Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI)
FDA Approval announced June 18, 2019.
Keytruda - KN-158
Small cell lung cancer (SCLC)
Phase 3 data due 2019.
ZERBAXA
Hospital-Acquired Bacterial Pneumonia
Phase 3 data due 2019.
MK-7655A
Hospital-Acquired Bacterial Pneumonia
Phase 2 data due 2019.
MK-8591
HIV

Latest News

  1. Here's Why I'm Sticking With Merck
  2. Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
  3. Merck's Keytruda Gets 2nd Label Expansion Approval in June
  4. The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut
  5. AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
  6. Merck (MRK) Outpaces Stock Market Gains: What You Should Know
  7. Merck KGaA -- Moody's: Versum shareholders approve acquisition by Merck KGaA
  8. Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
  9. AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
  10. Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
  11. FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
  12. LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
  13. UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
  14. Bayer to Invest 5 Billion Euros in Weedkiller Research
  15. J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
  16. Merck’s Inorganic Growth Strategy in 2019
  17. Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
  18. New Targets for Merck Stock as Charts Point Higher
  19. How Are Merck’s Revenues Trending in 2019?
  20. The 5 Worst Dow Jones Stocks So Far in 2019